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Objectives This study sought to evaluate thoracoscopic stand-alone left atrial appendectomy for thromboembolism preven-
tion in nonvalvular atrial fibrillation (AF).
Background Closing the left atrial appendage (LAA) is an efficacious alternative to oral anticoagulation as prevention against
AF-induced thromboembolism, provided that the procedure is safe and complete.
Methods Thirty patients (mean age, 74  5.0 years) who had had thromboembolisms were selected. A subgroup of 21
patients (mean age, 75 years; mean CHA2DS2 VASc score, 4.5) urgently needed an alternative treatment to anti-
coagulation: warfarin was contraindicated due to hemorrhagic side effects in 13, the international normalized
ratio was uncontrollable in 7, and transient ischemic attacks had developed immediately after the warfarin dose
was reduced for oncological treatment in 1. The LAA was thoracoscopically excised with an endoscopic cutter.
Results Thoracoscopic appendectomy (mean operating time, 32 min, switched to mini-thoracotomy in 2 cases) led to no
mortality and no major complications. Three-month post-operative 3-dimensional enhanced computed tomogra-
phy, performed with patients’ consent, confirmed the completeness of the appendectomy. Patients have been
followed for 1 to 38 months (mean, 16  9.7 months [18  9.4 months for the subgroup]). One patient died of
breast cancer 28 months after surgery. Despite discontinued anticoagulation, no patients have experienced re-
currence of thromboembolism.
Conclusions Thoracoscopic stand-alone appendectomy is potentially safe and may allow surgeons to achieve relatively sim-
ple, complete LAA closure. Further experience may demonstrate this technique to be a viable option for thrombo-
embolism prevention in nonvalvular AF. (J Am Coll Cardiol 2013;62:103–7) © 2013 by the American College of
Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.01.017Most clots originate in the left atrial appendage (LAA)
when atrial fibrillation (AF) is nonrheumatic, so that se-
questration of the LAA should prevent thromboembolism.
Various effective surgical and transcatheter techniques have
been devised to this end (1).
Blackshear et al. (2) have pioneered thoracoscopic surgi-
cal LAA closure aimed at preventing AF-induced stroke.
Their good clinical results encouraged us to develop a new
thoracoscopic technique for excising the LAA entirely from
its base; we have applied the method to selected patients
with nonvalvular ablation-refractory AF to prevent stroke
and other thromboembolism recurrence. This paper de-
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accepted January 2, 2013.scribes the early clinical outcomes of thoracoscopic stand-
alone appendectomy.
Methods
Patient selection. Thoracoscopic stand-alone appendec-
tomy was offered to nonvalvular AF patients for secondary
prevention of AF-induced thromboembolism on the con-
dition that AF was expected to be refractory to ablative
treatment. If AF was expected to be responsive to ablation,
the patients underwent extracardiac radiofrequency ablation
See page 119
thoracoscopically and were excluded from the study. AF was
judged to be ablation refractory when the patient manifested
significant heart remodeling in routine checkups. Cardio-
genicity of the thromboembolism was verified by neurolo-
gists, who used ultrasonography and magnetic resonance
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other ischemic etiologies. The
LAA had to be clotless, as con-
firmed by enhanced computed to-
mography of the left atrium (LA).
The patients had to be able to give
informed consent for the opera-
tion. The protocol was approved
by the institutional review board of
the authors’ institution.
Totally endoscopic LAA. The procedure was performed
by a single surgeon. Anticoagulation was discontinued the
day before surgery, after which intravenous drip infusion of
heparin was given. Each patient was anesthetized through a
double-lumen endotracheal tube and placed in the right
lateral recumbent position. Transesophageal echocardiogra-
phy (TEE) was performed with the patient in the optimal
position to display the LAA. The left lung was spontane-
ously deflated, and 4 endoscopic ports were made in the left
lateral thorax: one for a 5-mm, 45-degree camera, another
for an endoscopic cutter (EZ45G Endoscopic Linear Cut-
ter, Ethicon Endo-Surgery, Cincinnati, Ohio), and the
other 2 for endo-forceps. A 5-cm-long pericardiotomy was
made just above the LAA and 2 cm anterior to the left
phrenic nerve. The endoscopic cutter was introduced into
the chest, and the base of the LAA was divided (Fig. 1,
Online Video 1). A single chest tube was left in the pleural
cavity.
Follow-up. Patients underwent regular checkups, includ-
ing imaging examinations if necessary, to investigate throm-
boembolic symptoms. Three-dimensional enhanced com-
puted tomography of the LA was performed with patients’
consent 3 months after surgery.
Results
Most of the 14 male and 16 female subjects (mean age, 74
5.0 years; median age, 75 years; range, 61 to 84 years) (Table 1)
had had AF for 10 years. In all patients, heart remodeling
Abbreviations
and Acronyms
AF  atrial fibrillation
LA  left atrium
LAA  left atrial
appendage
TEE  transesophageal
echocardiography
Figure 1 Thoracoscopic Views of Left Atrial Appendectomy
(Left) The broken line represents a long axis of the oval-shaped appendage’s bas
seam. See accompanying Online Video 1. LAA  left atrial appendage.was significant; the LA diameter was dilated to 52 mm on
average (range, 46 to 61 mm), and the amplitude of
fibrillatory waves was 1 mm on the V1 electrocardiograph
lectrode. All 30 patients had had a previous thromboem-
olism; 29 had had strokes and/or transient ischemic attacks
TIAs), and 1 patient had had superior mesenteric artery
cclusion. Seven patients (23%) had had multiple episodes
f thromboembolism. Thus, all patients had received war-
arin for anticoagulation.
A subgroup of 21 patients (Patient #10 through #30; 10
en, 11 women; mean age, 75  5.5 years; median age, 76
ears; range, 61 to 83 years) urgently required alternative
reatment to warfarin. Twenty of these had a high risk of
mminent thromboembolism recurrence because of prob-
ems with the administration of warfarin: 13 had been
ommonly underdosed or often kept off warfarin due to
emorrhagic side effects (cerebral bleeding in 3 patients,
ersistent gastrointestinal bleeding in 9 patients [including
ccasional massive hemorrhoid bleeding in 1 patient], and
nidentified severe anemia in 1 patient). Six patients had
een continually underdosed because of difficulties control-
ing the international normalized ratio within the therapeu-
ic range recommended for elderly populations (3). In 1
atient who had been given warfarin for the first time for a
uperior mesenteric artery embolism, the international nor-
alized ratio had fluctuated uncontrollably, probably due to
igestive dysfunction caused by extensive bowel resection.
n another patient (a 66-year-old man with a diagnosis of
arly gastric cancer), the international normalized ratio was
rought down to 1.25 2 days before gastroscopic mucosal
esection, but the treatment had to be postponed because
ransient ischemic attacks soon developed and he went back
n full anticoagulation. Except in 3 patients, 1 with a history
f coronary artery bypass grafting, 1 with a midcerebral
rtery revascularization, and 1 with arteriosclerosis obliter-
ns in the lower extremity, aspirin had been avoided,
erhaps because of a report by the Japan Atrial Fibrillation
troke Trial (4) indicating that low-dose aspirin does not
wiched between endoscopic cutter’s legs. (Right) Arrows indicate a staplede sand
Patients Characteristics and OutcomesTable 1 Patients Characteristics and Outcomes
Anticoagulation History Follow-Up
Patient # Age, yrs Sex
AF
Duration, yrs
LA
Size, mm
Hemorrhagic
Side Effect
Warfarin
Before TE
TE/mRS
Score
CHADS2
(CHA2DS2-VASc)
Score
Interval Between TE and
Appendectomy (I <1 month, II
<1 month to <2 months, III
<2 months to <3 months)
Duration,
months Recurrence
1 74 M Unknown 60 None NE Stroke/0 2 (4) 2 yrs 24 None
2 73 F 10 51 None UD Stroke/0 3 (5) 7 yrs 22 None
3 69 M 10 48 None NE TIA/0 3 (4) 9 mo 19 None
4 71 F 10 52 None NE Stroke/0 3 (5) 6 yrs 14 None
5 72 F 10 54 None UD TIA/0 2 (4) 1 yr 10 None
6 74 M Unknown 51 None NE Stroke/1 3 (5) 1 yr 7 None
7 77 F Unknown 50 None NE Stroke/0 4 (5) 3 yrs 4 None
8 68 M 10 54 None UD TIA/0 2 (4) 10 months 1 None
9 74 F Unknown 50 None NE Stroke/0 3 (5) 1 yr 1 None
10 81 M 10 61 Hemorrhoid TH TIA/0 4 (5) II 38 None
11 76 F Unknown 58 Cerebral TH Stroke/2 5 (7) II 32 None
12 73 M 10 51 GI TH Stroke/1 3 (4) I 28 None
13 75 F 10 52 GI UD Stroke, TIA/1 3 (5) II 26 None
14 77 F 10 49 Unidentified anemia UD Stroke/1 4 (5) III 23 None
15 71 M 10 60 GI UD Stroke/2 3 (4) II 21 None
16 82 F Unknown 50 Cerebral TH Stroke, TIA/3 4 (5) III 21 None
17 69 M 10 54 GI UD Stroke/0 2 (3) I 19 None
18 73 F 10 50 GI UD Stroke/1 3 (5) II 15 None
19 79 F 10 48 Cerebral TH TIA/0 4 (5) II 14 None
20 70 M 10 53 GI UD Stroke/1 4 (5) I 13 None
21 72 F 10 49 GI UD TIA/0 3 (5) I 11 None
22 77 M 10 48 GI UD Stroke/0 4 (4) I 5 None
23* 78 F 10 51 None UD Stroke/0 4 (5) I 28 None
24 83 F 10 52 None UD Stroke/1 4 (5) II 19 None
25 79 M 10 52 None UD Stroke/1 4 (4) II 16 None
26 73 M 10 54 None UD Stroke/0 3 (4) I 12 None
27 76 F 10 50 None UD Stroke, TIA/1 4 (5) I 3 None
28 81 F 10 58 None UD TIA/0 4 (5) I 1 None
29† 61 M Unknown 46 None NE SMAO/NA 2 (2) III 24 None
30‡ 66 M 10 47 None UD TIA/0 2 (3) II 16 None
Subgroup is from #10 to #30. *Died of breast cancer. †Warfarin was given after SMAO but the international normalized ratio was uncontrollable after extensive bowel resection. ‡TIAs occurred as the international normalized ratio was reduced to 1.25 for oncological treatment.
AF  atrial fibrillation; LA  left atrium; GI  gastrointestinal; TE  thromboembolism; mRS modified Rankin scale; NE  no experience; UD  underdose; TH  temporary halt; TIA  transient ischemic attack; SMAO  superior mesenteric artery occlusion; NA  not
available.
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Rankin Scale scores were 0 for 9 of the patients, 1 for 8, 2
for 2, and 3 for 1. The mean CHADS2 and CHA2DS2
VASc scores were 3.5 (range, 2 to 5) and 4.5 (range, 2 to 7),
respectively. Surgery was performed within 1 month of
thromboembolism in 9 of the subgroup patients, 1 to 2
months after thromboembolism in 9 patients, and 2 to 3
months after in 3 patients.
Surgery took 32 min on average (range, 18 to 91 min).
Surgery was switched to mini-thoracotomy due to pericardial
or pleural adhesions in 2 patients (6.7%). Blood loss was
negligible, so no homologous blood products were used.
Intraoperative TEE clearly demonstrated in 26 patients (87%)
a spontaneous echo contrast in the LAA that vanished soon
after appendectomy (Fig. 2). The mean post-operative hospital
stay was 3.1 days (range, 2 to 6 days). The chest tube was
removed 24 h after surgery from all but 1 patient, who
experienced minor air leakage due to pleural adhesiolysis;
drainage was prolonged for 2 days. A minor wound compli-
cation occurred in 1 patient on hemodialysis, but no operative
death or major complications (e.g., stroke, cardiac events,
pulmonary morbidity, left phrenic palsy) occurred.
Aspirin was continued in the 3 preoperatively medicated
subgroup patients, but warfarin was discontinued in every
patient after appendectomy. Three-dimensional enhanced
computed tomography images of 19 patients (63%) obtained
3 months after surgery confirmed the absence of LAA stumps
and clots in the LA cavity (Fig. 3). Follow-up of the total
group of 30 patients ranged from 1 to 38 months, with a
median of 16 months and a mean of 16  9.7 months; the
corresponding figures for the subgroup were 1 to 38 months,
19 months, and 18  9.4 months, respectively. All patients
voided re-anticoagulation and recurrent thromboembolism.
he only death was a woman in the subgroup who died 28
onths later of breast cancer.
iscussion
ong-term oral anticoagulation is contraindicated in 14% to
Figure 2 Intraoperative Transesophageal Echocardiograms Bef
Intraoperative transesophageal echocardiograms before (left) and after (right) app0% patients with AF who are at risk of stroke (5), and useof newly available oral anticoagulants (e.g., dabigatran) is
still risky for elderly patients (6). Optional prophylactic
treatments must, therefore, be devised for vulnerable AF
patients.
When permanent closure of the LAA was demonstrated
to be an effective adjunct for stroke prevention in open-heart
surgery (7), both surgeons and catheter interventionists
focused on minimally invasive approaches to achieve this
simple procedure. However, the LAA closure is not easy for
2 reasons. First, the LAA is fragile. Blackshear et al. (2) had
1 case of catastrophic bleeding among 15 cases of thoraco-
scopic LAA ligation, and cardiac tamponade is an occa-
sional complication in transcutaneous LAA closure (8).
econd, complete closure of the LAA is technically de-
anding. A retrospective TEE study by Kanderian et al. (9)
ound that even via the open approach, only 60% of surgical
nd After Appendectomy
tomy. Arrow indicates a spontaneous echo contrast in the appendage.
Figure 3
3-Dimensional Image of the Left Atrium
Constructed by 3-Month Post-Operative-Enhanced
Computed Tomography
A stapled seam is encircled with a broken line; no stump is left.ore a
endec
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The percutaneous Watchman device has also been reported
to result in peridevice flow in 32% of implanted patients
(10). Incompletely closed LAAs may lead to continued clot
formations and stroke recurrence (11). One TEE study (12)
showed that 50% of incompletely ligated LAAs still pro-
duced thrombi and that 22% of them produced thrombo-
embolic events.
We devised the present technique with the aim of
materializing safe, complete, and minimally invasive LAA
closure. Anatomic understanding of the LAA is essential;
the LAA’s ostium is as thick as the LA wall, but its body is
thin and fragile, and the ostial plane is elliptical. We
speculate that this morphology might make the simple
extracardiac ligation of enlarged LAA bases with a suture or
the newly developing LARIAT device technically difficult
(13). In our technique, a long axis of the oval LAA ostium
(Fig. 1) is recognized, and the axis is extended until it
penetrates the chest wall. The intercostal site to be pene-
trated by this extended line, usually the seventh or eighth
intercostal space on the posterior axillary line, becomes the
port site for the endoscopic cutter. The LAA Occlusion
Study reported that 28% of stapled LAAs left stumps (14).
The failure is possibly due to suboptimal stapler angles
through sternotomy in addition to the lack of the intraop-
erative TEE guidance.
Early discontinuation of anticoagulation could be an
important benefit of thoracoscopic appendectomy, particu-
larly to patients like those in our subgroup. Nevertheless,
surgeons should know that thoracoscopy is challenging in
patients who have excessively thick chests, who cannot
tolerate 30-min hemipulmonary ventilation, or who have
diffuse, dense adhesions in the pericardial or pleural spaces.
Also, surgeons must keep in mind potential problems due to
instrumental malfunction and difficult troubleshooting in
thoracoscopic surgery; stapler malalignment may occur, and
its mishandling would cause uncontrollable bleeding. A
novel clip device may help reduce those potential risks (15).
Study limitations. This study has 2 main limitations. First,
the case volume is still small, and no randomized, controlled
comparisons with other therapeutic options were made.
Second, the mean follow-up period was relatively short.
Conclusions
Thoracoscopic stand-alone appendectomy is potentially safe
and may permit surgeons to remove the LAA relatively
simply and completely.
This procedure would benefit patients who are at great
risk of thromboembolisms and in whom anticoagulation is
no longer tolerable. Although the experience to date is
insufficient to address potential safety concerns associated
with applying the technique in a limited-access environ-
ment, further experience may demonstrate this to be a viable
option for thromboembolism protection in patients with
nonvalvular AF.Acknowledgment
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APPENDIX
For a supplementary video and its legend, please see the online version of
this article.
